ROCKVILLE, MD, the United States, and SUZHOU, China, November 28, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication – adult patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant and/or intolerant of first-and second-generation tyrosine Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, November 24, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, November 21, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, announced today that findings from a phase Ib multicenter clinical trial (NCT04260022) of its third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) have been Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, November 17, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that a New Drug Application (NDA) for its inhouse developed investigational novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), for the treatment Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, November 6, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the latest results from three clinical studies of one of the company’s key drug candidate, lisaftoclax (APG-2575), have been Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, November 6, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that multiple studies of its novel investigational drug candidate, olverembatinib (HQP1351), have been selected for presentations, including an Oral Report, Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, October 7, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that APG-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor (TKI), has been cleared by the Center for Drug Evaluation (CDE) of China’s Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, September 13, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the clinical data of olverembatinib (HQP1351), the company’s novel drug candidate, in patients with succinate dehydrogenase- Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, September 8, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced that it will present the latest clinical data of olverembatinib (HQP1351), the company’s novel drug candidate, in patients with succinate dehydrogenase- (SDH-) deficient Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, August 22, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced its 2024 interim results. During the reporting period, Ascentage Pharma continued to execute its global innovation strategy, having achieved breakthroughs across various aspects Read More ›